Drug Profile
Research programme: MerTK inhibitors - Rigel Pharmaceuticals
Alternative Names: Mer-Axl; R 992Latest Information Update: 28 May 2020
Price :
$50
*
At a glance
- Originator Rigel Pharmaceuticals
- Class Antineoplastics; Small molecules
- Mechanism of Action Proto-oncogene protein c-mer inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 May 2020 No recent reports of development identified for preclinical development in Cancer in USA
- 01 Dec 2018 Pharmacodynamics data from a from preclinical studies in Cancer presented at the 60th Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2018)
- 06 Jun 2016 Research programme: MerTK inhibitors - Rigel Pharmaceuticals is available for licensing as of 06 Jun 2016. http://www.rigel.com/index.php/about-rigel/current-partners/